The brand name drug industry and the state of Arkansas have agreed on a litigation plan that could lead to a quicker federal court decision than now anticipated on the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.
…
Category: Twitter
The American Hospital Association (AHA) yesterday asked U.S. House and Senate party leaders to ensure that a must-pass spending bill next month protects hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the
…
SPONSORED CONTENT
Drastic federal cuts to the 340B program. Alarming changes to Gilead’s Advancing Access Program. If your organization is a federal grantee or health system providing HIV care and/or prevention services, you know there has never been a more important time to future-proof your program—while still offering the highest standards of compassionate care.
What’s more, how entities provide care to their communities is
…
Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.
Please Login or Become a Paid Subscriber to
U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drives home the urgent need to pass robust drug pricing reforms.”
Please Login
SPONSORED CONTENT
Are you attending the upcoming 340B Coalition Winter Conference in San Diego? Join us for breakfast!
Marriott Marquis San Diego Marina
Monday, January 31 | 8:30 a.m. PT
Omnicell 340B will be hosting a panel discussion with some of the most respected long-term experts on the 340B program at the upcoming 340B Coalition
…
Groups that represent 340B hospitals yesterday slammed the multi-point 340B contract pharmacy policy that Bristol Meyers Squibb (BMS) released last Friday.
Leonard Stark, the federal judge who presided over AstraZeneca’s 340B contract pharmacy lawsuit from its start last year, is on the verge of being elevated to a higher court, possibly by the end of this week. If that happens before
…
A federal district judge on Friday held “pharma bro” Martin Shkreli liable for antitrust claims brought by the Federal Trade Commission (FTC) and seven states.
Please Login or Become a Paid Subscriber to View this Content
340B program flexibilities will continue under the eighth 90-day extension of the COVID-19 national public health emergency (PHE) late last week.
×
*Sign up for news summaries and alerts from 340B Report